An AllTrials project

NCT03732820: A reported trial by AstraZeneca

This trial has reported on time, in line with the regulations.

Full data

Full entry on ClinicalTrials.gov NCT03732820
Title A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)
Results Status Reported
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Oct. 31, 2018
Completion date July 30, 2021
Required reporting date July 30, 2022, midnight
Actual reporting date July 29, 2022
Date last checked at ClinicalTrials.gov Sept. 12, 2022
Days late None